Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Heston Blumenthal has revealed that he is taking the weight-loss drug Wegovy. The celebrity chef admitted his use of the drug ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...